184 related articles for article (PubMed ID: 8940714)
21. Monitoring liver tumor therapy with [18F]FDG positron emission tomography.
Nagata Y; Yamamoto K; Hiraoka M; Abe M; Takahashi M; Akuta K; Nishimura Y; Jo S; Masunaga S; Kubo S
J Comput Assist Tomogr; 1990; 14(3):370-4. PubMed ID: 2335602
[TBL] [Abstract][Full Text] [Related]
22. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group.
Price P; Jones T
Eur J Cancer; 1995 Nov; 31A(12):1924-7. PubMed ID: 8562143
[TBL] [Abstract][Full Text] [Related]
23. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose.
Rege SD; Hoh CK; Glaspy JA; Aberle DR; Dahlbom M; Razavi MK; Phelps ME; Hawkins RA
Cancer; 1993 Jul; 72(1):82-90. PubMed ID: 8389668
[TBL] [Abstract][Full Text] [Related]
24. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
25. FDG-PET for the evaluation of tumor viability after anticancer therapy.
Okada J; Oonishi H; Yoshikawa K; Imaseki K; Uno K; Itami J; Arimizu N
Ann Nucl Med; 1994 May; 8(2):109-13. PubMed ID: 8074956
[TBL] [Abstract][Full Text] [Related]
26. [Cancer screening with whole-body FDG PET].
Yasuda S; Ide M; Takagi S; Shohtsu A
Kaku Igaku; 1996 Oct; 33(10):1065-71. PubMed ID: 8952258
[TBL] [Abstract][Full Text] [Related]
27. PET FDG studies of Wilms tumors.
Shulkin BL; Chang E; Strouse PJ; Bloom DA; Hutchinson RJ
J Pediatr Hematol Oncol; 1997; 19(4):334-8. PubMed ID: 9256833
[TBL] [Abstract][Full Text] [Related]
28. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients.
Strauss LG
Eur J Nucl Med; 1996 Oct; 23(10):1409-15. PubMed ID: 8781149
[TBL] [Abstract][Full Text] [Related]
29. [Cancer detection with whole-body FDG PET images without attenuation correction].
Yasuda S; Ide M; Takagi S; Shohtsu A; Mitomi T; Kobayashi S; Suzuki Y
Kaku Igaku; 1996 Apr; 33(4):367-73. PubMed ID: 8683875
[TBL] [Abstract][Full Text] [Related]
30. Positron emission tomographic oncology.
Lawson MA
West J Med; 1994 Oct; 161(4):411-2. PubMed ID: 7817554
[No Abstract] [Full Text] [Related]
31. Comparison of low-dose dobutamine-gradient-echo magnetic resonance imaging and positron emission tomography with [18F]fluorodeoxyglucose in patients with chronic coronary artery disease. A functional and morphological approach to the detection of residual myocardial viability.
Baer FM; Voth E; Schneider CA; Theissen P; Schicha H; Sechtem U
Circulation; 1995 Feb; 91(4):1006-15. PubMed ID: 7850935
[TBL] [Abstract][Full Text] [Related]
32. Detection of malignancies with SPECT versus PET, with 2-[fluorine-18]fluoro-2-deoxy-D-glucose.
Martin WH; Delbeke D; Patton JA; Sandler MP
Radiology; 1996 Jan; 198(1):225-31. PubMed ID: 8539384
[TBL] [Abstract][Full Text] [Related]
33. Positron emission tomography in oncology. General acceptance of its role is overdue.
Lamki LM
Cancer; 1996 Nov; 78(10):2039-42. PubMed ID: 8918394
[No Abstract] [Full Text] [Related]
34. [Use of positron-emission tomography in oncology].
Strauss LG; Kabelitz D; Kremer B; Lode H; Meinertz T; Sauerbruch T; Sterry W
Dtsch Med Wochenschr; 1996 Feb; 121(7):207-9. PubMed ID: 8681765
[No Abstract] [Full Text] [Related]
35. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG).
Hubner KF; McDonald TW; Niethammer JG; Smith GT; Gould HR; Buonocore E
Gynecol Oncol; 1993 Nov; 51(2):197-204. PubMed ID: 8276294
[TBL] [Abstract][Full Text] [Related]
36. Introduction to imaging brain tumor metabolism with positron emission tomography (PET).
Conti PS
Cancer Invest; 1995; 13(2):244-59. PubMed ID: 7874578
[TBL] [Abstract][Full Text] [Related]
37. [Understanding positon emission tomography (PET) with [18F]-FDG in clinical oncology. Informations dedicated to patients and relatives].
Bourguet P; Brusco S; Corone C; Devillers A; Foehrenbach H; Lumbroso JD; Maszelin P; Montravers F; Moretti JL; Rain JD; Talbot JN; Carretier J; Leichtnam-Dugarin L; Delavigne V; Philip T; Fervers B; ; ; ; ; ; ;
Bull Cancer; 2005 Jul; 92(7):723-32. PubMed ID: 16123010
[TBL] [Abstract][Full Text] [Related]
38. Superimposition of PET images using 18F-fluorodeoxyglucose with magnetic resonance images in patients with pancreatic carcinoma.
Benyounes H; Smith FW; Campbell C; Evans NT; Norton MY; Mikecz P; Heys SD; Bruce D; Eremin O; Sharp PF
Nucl Med Commun; 1995 Jul; 16(7):575-80. PubMed ID: 7478396
[TBL] [Abstract][Full Text] [Related]
39. Staging of non-small-cell lung cancer by whole-body fluorine-18 deoxyglucose positron emission tomography.
Bury T; Dowlati A; Paulus P; Hustinx R; Radermecker M; Rigo P
Eur J Nucl Med; 1996 Feb; 23(2):204-6. PubMed ID: 8925857
[TBL] [Abstract][Full Text] [Related]
40. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography.
Ichiya Y; Kuwabara Y; Otsuka M; Tahara T; Yoshikai T; Fukumura T; Jingu K; Masuda K
J Nucl Med; 1991 Sep; 32(9):1655-60. PubMed ID: 1880564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
